The Vector Core Facility (Core B) will manufacture all the recombinant adenovirus (rAd) vaccines for the preclinical studies and the clinical trials described in this IPCAVD grant. Crucell Holland BV is a medium-sized biotechnology company that is dedicated to the development of vaccines for infectious diseases. In particular, Crucell has pioneered the development of rAd vector-based vaccines and has developed vaccine vectors from several Ad serotypes that have low seroprevalence in human populations. Crucell has also been a leader in the preclinical-to-clinical translational development of rAd vector-based vaccines. In particular, Crucell has developed robust production and purification methods to manufacture clinical-grade rAd vaccines that conform to all FDA and EC requirements, standardized and validated release assays, and developed several packaging cell lines that support pharmaceutical-scale manufacturing. Centralized production, purification, and quality control standards are critical to ensure the quality of the rAd vector-based vectors that will be used in the vaccine studies in this IPCAVD grant. This Core Facility will produce the research-grade rAd vaccines to support the preclinical studies described in Projects 1 and 2 and the clinical-grade rAd vaccines to support the clinical trials described in Project 2. We propose the following three Specific Aims for this Core Facility: 1. To manufacture, purify, and quality control research-grade rAd vaccines expressing HIV-1 and SIV antigens; 2. To manufacture, purify, quality control, and release clinical-grade rAd vaccines expressing HIV-1 antigens under Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) conditions; and 3. To coordinate preclinical toxicology studies under GLP conditions and prepare IND applications to support the initiation of phase I and phase II clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI066305-04
Application #
7603038
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
4
Fiscal Year
2008
Total Cost
$6
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Baden, Lindsey R; Karita, Etienne; Mutua, Gaudensia et al. (2016) Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med 164:313-22
Baden, Lindsey R; Liu, Jinyan; Li, Hualin et al. (2015) Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211:518-28
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2014) First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 210:1052-61
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2013) First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207:240-7
Barouch, Dan H; Whitney, James B; Moldt, Brian et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224-8
Barouch, Dan H; Liu, Jinyan; Peter, Lauren et al. (2013) Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 207:248-56
Stephenson, Kathryn E; SanMiguel, Adam; Simmons, Nathaniel L et al. (2012) Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol 86:11434-40
Li, Hualin; Rhee, Elizabeth G; Masek-Hammerman, Katherine et al. (2012) Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 86:10862-5
Handley, Scott A; Thackray, Larissa B; Zhao, Guoyan et al. (2012) Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 151:253-66
Bradley, Ritu R; Maxfield, Lori F; Lynch, Diana M et al. (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86:1267-72

Showing the most recent 10 out of 43 publications